VidaMed v Prosurge
This article was originally published in The Gray Sheet
Federal judge grants VidaMed summary judgment in support of the company's assertion that ProSurge infringes a VidaMed patent by "asking, encouraging and otherwise soliciting physicians" to use ProSurge's infringing Opal and Opal Flex products for treatment of benign prostatic hyperplasia. The California federal court rules that the VidaMed patent covered basic methods for treatment involving the use of one or more radiofrequency electrodes deployed transurethrally to ablate prostatic tissue
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.